{
  "version": "1.0",
  "schema": "https://entitymap.org/spec/v1.0",
  "publisher": {
    "name": "Ketalux",
    "url": "https://ketalux.com",
    "sameAs": "https://en.wikipedia.org/wiki/Ketamine"
  },
  "generated": "2026-06-15T00:00:00Z",
  "profile": "core",
  "verificationStatus": "self-declared",
  "entities": [
    {
      "entityId": "e_ketamine",
      "@type": "Concept",
      "name": "Ketamine",
      "description": "A dissociative anesthetic medication studied for rapid-acting antidepressant effects and used in supervised mental health treatment protocols.",
      "sameAs": "https://en.wikipedia.org/wiki/Ketamine",
      "hasChunks": [
        {
          "chunkId": "c_ketamine_1",
          "text": "Ketamine is a dissociative anesthetic that has emerged as a rapid-acting treatment explored in psychiatry, particularly for treatment-resistant depression and other mood disorders.",
          "sourceUrl": "https://ketalux.com/what-is-ketamine-therapy",
          "pageTitle": "What is Ketamine Therapy",
          "publisher": "Ketalux"
        }
      ],
      "relations": [
        { "predicate": "TREATS", "targetId": "e_depression", "targetName": "Major Depressive Disorder", "confidence": "declared" },
        { "predicate": "TREATS", "targetId": "e_ptsd", "targetName": "Post-Traumatic Stress Disorder", "confidence": "declared" },
        { "predicate": "ACTS_ON", "targetId": "e_nmda", "targetName": "NMDA Receptor", "confidence": "declared" }
      ]
    },
    {
      "entityId": "e_kap",
      "@type": "Methodology",
      "name": "Ketamine-Assisted Psychotherapy",
      "description": "A clinical protocol combining supervised ketamine administration with psychotherapy sessions to support integration of the experience.",
      "sameAs": "https://en.wikipedia.org/wiki/Ketamine#Psychiatric_use",
      "hasChunks": [
        {
          "chunkId": "c_kap_1",
          "text": "Ketamine-assisted psychotherapy pairs medically supervised ketamine dosing with structured therapeutic support, including preparation and integration sessions.",
          "sourceUrl": "https://ketalux.com/how-treatment-works",
          "pageTitle": "How Ketamine Treatment Works",
          "publisher": "Ketalux"
        }
      ]
    },
    {
      "entityId": "e_depression",
      "@type": "Concept",
      "name": "Major Depressive Disorder",
      "description": "A mood disorder characterized by persistent low mood, loss of interest, and functional impairment, sometimes studied as a target for ketamine therapy.",
      "sameAs": "https://en.wikipedia.org/wiki/Major_depressive_disorder",
      "hasChunks": [
        {
          "chunkId": "c_dep_1",
          "text": "Ketamine has been studied for major depressive disorder, particularly treatment-resistant depression, showing rapid symptom reduction in clinical trials.",
          "sourceUrl": "https://ketalux.com/ketamine-for-depression",
          "pageTitle": "Ketamine for Depression",
          "publisher": "Ketalux"
        }
      ]
    },
    {
      "entityId": "e_ptsd",
      "@type": "Concept",
      "name": "Post-Traumatic Stress Disorder",
      "description": "A trauma-related disorder researched as a potential target for ketamine-based interventions alongside trauma-focused therapy.",
      "sameAs": "https://en.wikipedia.org/wiki/Post-traumatic_stress_disorder",
      "hasChunks": [
        {
          "chunkId": "c_ptsd_1",
          "text": "Emerging research investigates ketamine as an adjunct in PTSD treatment, often combined with trauma-focused psychotherapy.",
          "sourceUrl": "https://ketalux.com/ketamine-for-ptsd",
          "pageTitle": "Ketamine for PTSD",
          "publisher": "Ketalux"
        }
      ]
    },
    {
      "entityId": "e_anxiety",
      "@type": "Concept",
      "name": "Anxiety Disorders",
      "description": "A category of mental health conditions including generalized anxiety disorder studied in the context of ketamine therapy research.",
      "sameAs": "https://en.wikipedia.org/wiki/Anxiety_disorder",
      "hasChunks": [
        {
          "chunkId": "c_anx_1",
          "text": "Preliminary studies suggest ketamine may reduce symptoms of generalized anxiety and social anxiety in carefully selected patients.",
          "sourceUrl": "https://ketalux.com/ketamine-for-anxiety",
          "pageTitle": "Ketamine for Anxiety",
          "publisher": "Ketalux"
        }
      ]
    },
    {
      "entityId": "e_ocd",
      "@type": "Concept",
      "name": "Obsessive-Compulsive Disorder",
      "description": "A mental health condition characterized by obsessions and compulsions, explored as an investigational target for ketamine treatment.",
      "sameAs": "https://en.wikipedia.org/wiki/Obsessive%E2%80%93compulsive_disorder",
      "hasChunks": [
        {
          "chunkId": "c_ocd_1",
          "text": "Early-phase trials have explored ketamine's potential to reduce obsessive-compulsive symptoms, though evidence remains preliminary.",
          "sourceUrl": "https://ketalux.com/ketamine-for-ocd",
          "pageTitle": "Ketamine for OCD",
          "publisher": "Ketalux"
        }
      ]
    },
    {
      "entityId": "e_esketamine",
      "@type": "Concept",
      "name": "Esketamine",
      "description": "The S-enantiomer of ketamine, available as an intranasal formulation approved for treatment-resistant depression.",
      "sameAs": "https://en.wikipedia.org/wiki/Esketamine",
      "hasChunks": [
        {
          "chunkId": "c_esk_1",
          "text": "Esketamine is the S-enantiomer of ketamine, delivered intranasally under medical supervision and approved for treatment-resistant depression.",
          "sourceUrl": "https://ketalux.com/modalities/intranasal-esketamine",
          "pageTitle": "Intranasal Esketamine",
          "publisher": "Ketalux"
        }
      ]
    },
    {
      "entityId": "e_nmda",
      "@type": "Concept",
      "name": "NMDA Receptor",
      "description": "A glutamate receptor central to ketamine's pharmacological action, implicated in synaptic plasticity and antidepressant mechanisms.",
      "sameAs": "https://en.wikipedia.org/wiki/NMDA_receptor",
      "hasChunks": [
        {
          "chunkId": "c_nmda_1",
          "text": "Ketamine acts primarily as an antagonist at the NMDA glutamate receptor, a mechanism linked to its rapid antidepressant effects.",
          "sourceUrl": "https://ketalux.com/mechanisms/nmda-receptors",
          "pageTitle": "NMDA Receptors and Ketamine",
          "publisher": "Ketalux"
        }
      ]
    },
    {
      "entityId": "e_neuroplasticity",
      "@type": "Concept",
      "name": "Neuroplasticity",
      "description": "The brain's capacity to reorganize synaptic connections, hypothesized to underlie ketamine's sustained therapeutic effects.",
      "sameAs": "https://en.wikipedia.org/wiki/Neuroplasticity",
      "hasChunks": [
        {
          "chunkId": "c_neuro_1",
          "text": "Ketamine appears to promote synaptogenesis and neuroplasticity, which may contribute to its sustained therapeutic benefit beyond acute dosing.",
          "sourceUrl": "https://ketalux.com/mechanisms/synaptogenesis",
          "pageTitle": "Synaptogenesis and Neuroplasticity",
          "publisher": "Ketalux"
        }
      ]
    },
    {
      "entityId": "e_bdnf",
      "@type": "Concept",
      "name": "Brain-Derived Neurotrophic Factor",
      "description": "A neurotrophin involved in neuronal growth and plasticity, implicated in mTOR-mediated mechanisms of ketamine response.",
      "sameAs": "https://en.wikipedia.org/wiki/Brain-derived_neurotrophic_factor",
      "hasChunks": [
        {
          "chunkId": "c_bdnf_1",
          "text": "BDNF signaling and mTOR pathway activation are implicated in the rapid antidepressant effects observed after ketamine administration.",
          "sourceUrl": "https://ketalux.com/mechanisms/bdnf-mtor",
          "pageTitle": "BDNF and mTOR Mechanisms",
          "publisher": "Ketalux"
        }
      ]
    },
    {
      "entityId": "e_iv_ketamine",
      "@type": "Methodology",
      "name": "Intravenous Ketamine Infusion",
      "description": "A clinical modality delivering subanesthetic ketamine doses via IV infusion under medical monitoring.",
      "sameAs": "https://en.wikipedia.org/wiki/Intravenous_therapy",
      "hasChunks": [
        {
          "chunkId": "c_iv_1",
          "text": "Intravenous ketamine is administered as a subanesthetic infusion over roughly 40 minutes under medical supervision, the most studied delivery route in depression research.",
          "sourceUrl": "https://ketalux.com/modalities/iv",
          "pageTitle": "IV Ketamine Modality",
          "publisher": "Ketalux"
        }
      ]
    },
    {
      "entityId": "e_safety",
      "@type": "Concept",
      "name": "Ketamine Safety and Contraindications",
      "description": "Clinical considerations covering side effects, drug interactions, and patient populations for whom ketamine is not appropriate.",
      "sameAs": "https://en.wikipedia.org/wiki/Ketamine#Adverse_effects",
      "hasChunks": [
        {
          "chunkId": "c_safety_1",
          "text": "Ketamine therapy carries cardiovascular, dissociative, and bladder-related risks, and is contraindicated in uncontrolled hypertension, psychosis, and certain other conditions.",
          "sourceUrl": "https://ketalux.com/safety-and-risks",
          "pageTitle": "Safety and Risks",
          "publisher": "Ketalux"
        }
      ]
    }
  ]
}